HIPAA Alert: Potential Data Breach Learn More

Close this search box.

Multiple Myeloma

Multiple Myeloma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

33 Clinical Trials
Multiple Myeloma Phase I/II Accepting Patients
nct/study# NCT02773030 / CC-220-MM-001

A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma

Learn More
Multiple Myeloma Phase I Accepting Patients
nct/study# NCT04142619 / UCARTS1A

Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma

Learn More
Multiple Myeloma N/A Accepting Patients
nct/study# NCT04458831 / IONA OBS16577

A Prospective, Non-Interventional, Multinational, Observational Study With Isatuximab In Patients With Relapsed And/Or Refractory Multiple Myeloma (RRMM)

Learn More
Multiple Myeloma NA Accepting Patients

Collection Of Biological Specimen

Learn More
Multiple Myeloma N/A Accepting Patients
nct/study# NCT04150289 / RECOMM

A Disease Registry Encompassing The Care Of Patients With Multiple Myeloma On Panobinostat (RECOMM)

Learn More
Multiple Myeloma Phase II Accepting Patients
nct/study# NCT04133636 / 68284528MMY2003

A Phase 2, Multicohort Open-Label Study Of JNJ-68284528, A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA In Subjects With Multiple Myeloma (CARTITUDE 2)

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.